Troubled Immunomedics now hit with CRL for breast cancer drug candidate
admin 18th January 2019 Uncategorised 0The troubles for troubled Immunomedics keep piling up. The New Jersey-based biotech, which has gone through a failed tie-up deal, boardroom cleansing and FDA Form 483 issues, today reported it has received a complete response letter from the FDA related to manufacturing concerns around its antibody-drug conjugate for breast cancer.
More: Troubled Immunomedics now hit with CRL for breast cancer drug candidate
Source: fierce